logo

Syndax Pharma (SNDX)



Trade SNDX now with
  Date
  Headline
5/30/2018 4:06:03 PM Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
5/17/2018 7:13:14 AM Syndax Announces Updated Results From Phase 2 ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA
1/10/2018 7:04:23 AM Syndax Says Clinical Collaboration To Evaluate Entinostat In Combination With Anti-PD-L1 Cancer Immunotherapy
1/5/2018 1:22:41 PM B. Riley FBR Starts Syndax Pharma (SNDX) At Buy With $40.00 Price Target
10/17/2017 7:07:17 AM Syndax Pharma Enters Worldwide License Agreement With Vitae Pharma For Allergan's Portfolio Of Menin-MLL Inhibitors
10/17/2017 7:04:04 AM Syndax Plans $25 Mln Registered Direct Offering Of Common Stock
10/5/2017 7:07:58 AM Syndax Announces Dosing Of First Patient In Pivotal Trial Of Entinostat For Breast Cancer In Japan
3/16/2017 8:55:28 AM FBR Capital Markets Starts Syndax Pharma (SNDX) At Outperform With $27 Price Target
2/9/2017 7:11:31 AM Syndax Pharma Names Richard Shea CFO, Effective Feb. 13
1/5/2017 7:04:20 AM Syndax Pharma Appoints Pierre Legault To Its Board
8/9/2016 6:37:26 AM Syndax Pharma Q2 Net Loss $8.4 Mln Or $0.47/shr Vs. Net Loss $26.3 Mln Or $440.52/shr Last Year